Lung Cancer Clinical Trials

Showing 2421-2440 of 4,288 trials

LUng CAncer focuS - Long-term Monitoring of Bronchogenic Carcinoma Patients (LUCAS)

NCT04228237

Long-term non-interventional monitoring of diagnostics and treatment patterns in newly diagnosed patients in selected pneumology centers in Czech republic.

Lung Cancer

Ceska Lekarska Spolecnost Jana Evangelisty Purkyne z.s.2,300 participantsStarted Jun 2018

Brno, Czechia • Hradec Králové, Czechia • Olomouc, Czechia +4 more locations

UNKNOWNPhase 2

Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC).

NCT04690686

This pilot study aims to evaluate the short-term and long-term safety, tolerability, and effectiveness of immunopheresis with the LW-02 column in removal of sTNFRs from plasma of patients with advanced, refractory NSCLC and to detect a potential disease control signal when employed in combination with low dose chemotherapy (ie, paclitaxel), immunotherapy (ie, atezolizumab) in patients who already failed first-line therapy, or as monotherapy in patients who already have failed second-line therapy.

Non Small Cell Lung Cancer

Immunicom Inc24 participantsStarted Oct 2020

Istanbul, Kucukcekmece, Turkey (Türkiye) • Istanbul, Sariyer, Turkey (Türkiye) • Istanbul, Uskudar, Turkey (Türkiye)

LUng CAncer focuS - Long-term Monitoring of Bronchogenic Carcinoma Patients (LUCAS)

Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC).

Related Searches

Breathe Anew for Lung Cancer Survivorship

Improving Implementation of Lung Cancer Screening in Diverse Populations II

Early Access Program of Lazertinib in Republic of Korea

Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer

Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study

TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

Appropriate Dosing to Optimise Personalised Cancer Treatments

A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

Cardiac Substructure Radiation Dose and Early Clinical Monitoring of Stage N2-3 Non-Small Cell Lung Cancer

Comparison of Robotic Arm-assisted PET/CT-guided Lung Biopsy With PET Fused CT- Fluoroscopy-guided Lung Biopsy

PEN-866 in Patients With Advanced Solid Malignancies

The Use and Effectiveness of Balloon for Endobronchial Ultrasonography

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Functional Imaging of Treatment Effects: A Companion Protocol to a Study of Extracranial Stereotactic Radioablation in Early Stage Non-Small Cell Lung Cancer

Safety Study of MGA271 in Refractory Cancer

Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer